Testing new medications to prevent serious liver complications

This is a large study testing whether retatrutide or tirzepatide—two new injectable medications—can prevent major liver complications in people who have fatty liver disease (called metabolic dysfunction-associated steatotic liver disease, or MASLD) and are at higher risk for serious outcomes. You'll be randomly assigned to receive one of the two medications or a placebo, and the study will follow you for about 4.5 years to see if the medication helps protect your liver.

Fatty liver disease is becoming more common and can progress to serious liver damage or failure. Right now, there are limited treatment options that can stop or slow this progression. This study is testing whether this medication can prevent that dangerous progression and avoid the need for a liver transplant.